EMA recommends conditional marketing authorisation in Europe for teclistamab for relapsed and refractory myelomaAccess, Myeloma28 July 2022
Myeloma Patients Europe (MPE) relaunches Myeloma Access Atlas platformAccess, MPE, Myeloma19 October 2021
Research Grant Application – Shared-Decision Making in MyelomaMPE, Myeloma, Patient evidence11 October 2021
Impact of the COVID-19 pandemic on the healthcare and lives of myeloma or AL amyloidosis patients and their caregiversAL amyloidosis, MPE, Myeloma, Patient evidence21 June 2021
EHA 2021| Daratumumab plus lenalidomide and dexamethasone (D-Rd) shows overall survival benefit in elderly patients with transplant-ineligible newly diagnosed myelomaConferences, Myeloma14 June 2021
EHA 2021 | Daratumumab maintenance improves Progression-Free Survival (PFS) after autologous stem cell transplantation in myelomaConferences, Myeloma13 June 2021
EHA 2021 | Patient preferences in myeloma, a qualitative multinational study in myelomaConferences, Myeloma11 June 2021
